Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 12/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.47 |
| ▸ | FLT1 | P17948 | 5/20 | 0.47 |
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | FLT4 | P35916 | 3/20 | 0.47 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3073063 | 0.99 | CCR4 (0.56) | CCR4FGFR1FLT1KDREGFR | |
| SCHEMBL3097391 | 0.90 | CCR4 (0.57) | CCR4FGFR1FLT1KDREGFR | |
| Hydrochloric Acid SCHEMBL3097742 | 0.89 | CCR4 (0.57) | CCR4FGFR1FLT1KDREGFR | |
| SCHEMBL3082876 | 0.83 | CCR4 (0.61) | CCR4FGFR1FLT1KDREGFR | |
| Hydrochloric Acid SCHEMBL3086854 | 0.82 | CCR4 (0.60) | CCR4FGFR1FLT1KDREGFR | |
| SCHEMBL13144554 | 0.80 | CCR4 (0.60) | CCR4FGFR1FLT1KDREGFR | |
| SCHEMBL13144560 | 0.80 | CCR4 (0.63) | CCR4FGFR1FLT1KDREGFR | |
| SCHEMBL3095907 | 0.79 | CCR4 (0.63) | CCR4FGFR1FLT1KDREGFR | |
| SCHEMBL13144550 | 0.79 | CCR4 (0.63) | CCR4FGFR1FLT1KDREGFR | |
| SCHEMBL3088637 | 0.77 | CCR4 (0.62) | CCR4FGFR1FLT1KDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790884-B2 | Acylaminopiperidine compound | ASTELLAS PHARMA INC. (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20090131666-A1 | ACYLAMINOPIPERIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-2000469-A9 | ACYLAMINOPIPERIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-2000469-A2 | ACYLAMINOPIPERIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2008-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131666-A1 | ACYLAMINOPIPERIDINE COMPOUND | CCR4, CCR1, CCR3 | CCR4 1/4885FGFR1 2439/4885FLT1 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.